INTRODUCTION.
In the last two decades, pharmacotherapy for obesity and type 2 diabetes mellitus has evolved toward drugs that target the incretin system, such as semaglutide, a glucagon-like peptide-1 (GLP-1) receptoragonist, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 recept...
E. M. Eliseeva, A. A. Druzhinina, A. A. Chistokhina· Safety and Risk of Pharmacot...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.